Health Trials

Clinical trials

5

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).

Participants needed: 153
Trial details
Phase: Phase 2, Phase 3Age: 1-17Biological sex: AllType: InterventionalSponsor: Crinetics Pharmaceuticals Inc.Updated: Aug 12, 2026Locations: 44
Eligibility criteria

Male or female at birth, between 1 to <18 years of chronological age at the time... [+5]

Diagnosis of any form of CAH other than classic 21-OHD. [+9]

Read more
Status: Recruiting

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.

Participants needed: 150
Trial details
Phase: Phase 3Age: 18-74Biological sex: AllType: InterventionalSponsor: Crinetics Pharmaceuticals Inc.Updated: Aug 12, 2026Locations: 63
Eligibility criteria

Male or female, between ≥18 to <75 years of age at the time of signing the ICF. [+8]

Diagnosis of any form of CAH other than classic 21-OHD. [+9]

Read more
Status: Recruiting

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome.

Participants needed: 141
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Crinetics Pharmaceuticals Inc.Updated: Aug 4, 2026Locations: 67
Eligibility criteria

Male or female ≥18 years of age, at the time of Screening. [+5]

Diarrhea attributed to any condition(s) other than carcinoid syndrome. [+11]

Read more
Status: Recruiting

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.

Participants needed: 150
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Crinetics Pharmaceuticals Inc.Updated: Jul 31, 2026Locations: 27
Eligibility criteria

Have a histological diagnosis of metastatic or locally advanced inoperable NET,... [+3]

Have tumor progression while undergoing a course of PRRT or within 6 months of c... [+8]

Read more
Status: Recruiting

An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).

Participants needed: 200
Trial details
Phase: Phase 2Age: 16-74Biological sex: AllType: InterventionalSponsor: Crinetics Pharmaceuticals Inc.Updated: Jun 29, 2026Locations: 13
Eligibility criteria

Participants with CAH who have completed the Treatment Period in a Crinetics par... [+8]

Any medical condition(s) or laboratory findings that, in the opinion of the Inve... [+14]

Read more